Glycoprotein YKL-40 Levels in Plasma Are Associated with Fibrotic Changes on HRCT in Asbestos-Exposed Subjects

Mediators of Inflammation

Volumn 2017, Issue , 2017, Pages

  Väänänen, Tuija ^a   Lehtimäki, Lauri ^b   Vuolteenaho, Katriina ^a   Hämäläinen, Mari ^a   Oksa, Panu ^b   Vierikko, Tuula ^c   Järvenpää, Ritva ^a,b   Uitti, Jukka ^b,d   Kankaanranta, Hannu ^b   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; C REACTIVE PROTEIN; COMPLEMENT FACTOR D; GELATINASE B; GLYCOPROTEIN; GLYCOPROTEIN YKL 40; INTERLEUKIN 6; UNCLASSIFIED DRUG; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1;

ADULT; ARTICLE; ASBESTOSIS; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PROTEIN BLOOD LEVEL; AGED; BLOOD; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; FEMALE; METABOLISM; MIDDLE AGED;

AGED; ASBESTOS; C-REACTIVE PROTEIN; CHITINASE-3-LIKE PROTEIN 1; COMPLEMENT FACTOR D; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY FIBROSIS;

EID: 85019987785     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2017/1797512     Document Type: Article

References (45)

1. G. Liu, P. Cheresh, and D. W. Kamp, "Molecular basis of asbestos-induced lung disease, " Annual Review of Pathology, vol. 8, pp. 161-187, 2013.
2. Orphanet, " March 2017, http://www.orpha.net.
3. EU commision public health policy on rare diseases, " March 2017, http://ec.europa.eu/health/rare-diseases/policy-en.
4. L. Stayner, L. S. Welch, and R. Lemen, "The worldwide pandemic of asbestos-related diseases, " Annual Review of Public Health, vol. 34, pp. 205-216, 2013.
5. T. Kameda, K. Takahashi, R. Kim et al., "Asbestos: use, bans and disease burden in Europe, " Bulletin of the World Health Organization, vol. 92, no. 11, pp. 790-797, 2014.
6. WHO I asbestos: elimination of asbestos-related diseases, fact sheet, " March 2017, http://www.who.int/mediacentre/factsheets/fs343/en/.
7. F. D. Coffman, "Chitinase 3-like-1 (CHI3L1): A putative disease marker at the interface of proteomics and glycomics, " Critical Reviews in Clinical Laboratory Sciences, vol. 45, no. 6, pp. 531-562, 2008.
8. C. G. Lee, C. A. Da Silva, C. S. Dela Cruz et al., "Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury, " Annual Review of Physiology, vol. 73, pp. 479-501, 2011.
9. Y. Zhou, H. Peng, H. Sun et al., "Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis, " Science Translational Medicine, vol. 6, no. 240, p. 240ra76, 2014.
10. M. Di Rosa, G. Malaguarnera, C. De Gregorio, F. Drago, and L. Malaguarnera, "Evaluation of CHI3L-1 and CHIT-1 expression in differentiated and polarized macrophages, " Inflammation, vol. 36, no. 2, pp. 482-492, 2013.
11. J. S. Johansen, S. Moller, P. A. Price et al., "Plasma YKL-40: A new potential marker of fibrosis in patients with alcoholic cirrhosis?" Scandinavian Journal of Gastroenterology, vol. 32, no. 6, pp. 582-590, 1997.
12. J. S. Johansen, P. Christoffersen, S. Moller et al., "Serum YKL-40 is increased in patients with hepatic fibrosis, " Journal of Hepatology, vol. 32, no. 6, pp. 911-920, 2000.
13. C. Nojgaard, J. S. Johansen, E. Christensen et al., "Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease, " Journal of Hepatology, vol. 39, no. 2, pp. 179-186, 2003.
14. Y. Saitou, K. Shiraki, Y. Yamanaka et al., "Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCVassociated liver disease, " World Journal of Gastroenterology, vol. 11, no. 4, pp. 476-481, 2005.
15. K. Furuhashi, T. Suda, Y. Nakamura et al., "Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis, " Respiratory Medicine, vol. 104, no. 8, pp. 1204-1210, 2010.
16. N. M. Korthagen, C. H. van Moorsel, P. Zanen, H. J. Ruven, and J. C. Grutters, "Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias, " Lung, vol. 192, no. 6, pp. 975-980, 2014.
17. X. Long, X. He, S. Ohshimo et al., "Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis, " The European Respiratory Journal, vol. 49, no. 2, article 1501924, 2017.
18. L. Lehtimäki, P. Oksa, R. Järvenpää et al., "Pulmonary inflammation in asbestos-exposed subjects with borderline parenchymal changes on HRCT, " Respiratory Medicine, vol. 104, no. 7, pp. 1042-1049, 2010.
19. O. Huuskonen, L. Kivisaari, A. Zitting, K. Taskinen, A. Tossavainen, and T. Vehmas, "High-resolution computed tomography classification of lung fibrosis for patients with asbestos-related disease, " Scandinavian Journal of Work, Environment & Health, vol. 27, no. 2, pp. 106-112, 2001.
20. S. Leivo-Korpela, L. Lehtimäki, R. Nieminen et al., "Adipokine adipsin is associated with the degree of lung fibrosis in asbestos-exposed workers, " Respiratory Medicine, vol. 106, no. 10, pp. 1435-1440, 2012.
21. N. M. Korthagen, C. H. van Moorsel, N. P. Barlo et al., "Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis, " Respiratory Medicine, vol. 105, no. 1, pp. 106-113, 2011.
22. J. S. Johansen, N. Milman, M. Hansen, C. Garbarsch, P. A. Price, and N. Graudal, "Increased serum YKL-40 in patients with pulmonary sarcoidosis-A potential marker of disease activity?" Respiratory Medicine, vol. 99, no. 4, pp. 396-402, 2005.
23. P. Jaksch, S. Taghavi, W. Klepetko, and M. Salama, "Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations independently predict bronchiolitis obliterans development in lung transplant recipients, " The Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 1, pp. 273-281, 2014.
24. A. Hector, M. S. Kormann, I. Mack et al., "The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease, " PLoS One, vol. 6, no. 9, article e24399, 2011.
25. T. Rath, L. Zwaschka, L. Hage et al., "Identification of neutrophil activation markers as novel surrogate markers of CF lung disease, " PLoS One, vol. 9, no. 12, article e115847, 2014.
26. C. Nordenbaek, J. S. Johansen, P. Halberg et al., "High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement, " Scandinavian Journal of Rheumatology, vol. 34, no. 4, pp. 293-297, 2005.
27. M. Corradi, M. Goldoni, R. Alinovi et al., "YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis, " Anticancer Research, vol. 33, no. 12, pp. 5517-5524, 2013.
28. P. J. Murray and T. A. Wynn, "Protective and pathogenic functions of macrophage subsets, " Nature Reviews Immunology, vol. 11, no. 11, pp. 723-737, 2011.
29. C. G. Lee, D. Hartl, G. R. Lee et al., "Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis, " The Journal of Experimental Medicine, vol. 206, no. 5, pp. 1149-1166, 2009.
30. Y. Nishimura, M. Maeda, N. Kumagai-Takei et al., "Altered functions of alveolar macrophages and NK cells involved in asbestos-related diseases, " Environmental Health and Preventive Medicine, vol. 18, no. 3, pp. 198-204, 2013.
31. H. F. Bigg, R. Wait, A. D. Rowan, and T. E. Cawston, "The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation, " The Journal of Biological Chemistry, vol. 281, no. 30, pp. 21082-21095, 2006.
32. K. M. Henningsen, S. K. Therkelsen, J. S. Johansen, H. Bruunsgaard, and J. H. Svendsen, "Plasma YKL-40, a new biomarker for atrial fibrillation?" Europace, vol. 11, no. 8, pp. 1032-1036, 2009.
33. P. Przybylowski, L. Janik, G. Wasilewski, E. Nowak, P. Kozlik, and J. Malyszko, "YKL-40, a novel marker of cardiovascular complications, is related to kidney function in heart transplant recipients, " Transplantation Proceedings, vol. 46, no. 8, pp. 2860-2863, 2014.
34. A. R. Nielsen, C. Erikstrup, J. S. Johansen et al., "Plasma YKL-40: A BMI-independent marker of type 2 diabetes, " Diabetes, vol. 57, no. 11, pp. 3078-3082, 2008.
35. T. Matsumoto and T. Tsurumoto, "Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters, " Clinical and Experimental Rheumatology, vol. 19, no. 6, pp. 655-660, 2001.
36. G. U. Okyay, R. E. Er, M. Y. Tekbudak et al., "Novel inflammatory marker in dialysis patients: YKL-40, " Therapeutic Apheresis and Dialysis, vol. 17, no. 2, pp. 193-201, 2013.
37. T. Väänänen, A. Koskinen, E. L. Paukkeri et al., "YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints, " Mediators of Inflammation, vol. 2014, Article ID 215140, p. 7, 2014.
38. R. Lieder and O. E. Sigurjonsson, "The effect of recombinant human interleukin-6 on osteogenic differentiation and YKL-40 expression in human, bone marrow-derived mesenchymal stem cells, " BioResearch Open Access, vol. 3, no. 1, pp. 29-34, 2014.
39. S. Ilavska, E. Jahnova, J. Tulinska et al., "Immunological monitoring in workers occupationally exposed to asbestos, " Toxicology, vol. 206, no. 2, pp. 299-308, 2005.
40. H. Lehtonen, P. Oksa, L. Lehtimäki et al., "Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis, " Thorax, vol. 62, no. 7, pp. 602-607, 2007.
41. F. O. Martinez and S. Gordon, "The M1 and M2 paradigm of macrophage activation: Time for reassessment, " F1000Prime Reports, vol. 6, no. 13.10, p. 12703, 2014.
42. S. Letuve, A. Kozhich, N. Arouche et al., "YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages, " Journal of Immunology, vol. 181, no. 7, pp. 5167-5173, 2008.
43. S. J. Park, Y. J. Jun, T. H. Kim et al., "Increased expression of YKL-40 in mild and moderate/severe persistent allergic rhinitis and its possible contribution to remodeling of nasal mucosa, " American Journal of Rhinology & Allergy, vol. 27, no. 5, pp. 372-380, 2013.
44. S. Libreros, R. Garcia-Areas, Y. Shibata, R. Carrio, M. Torroella-Kouri, and V. Iragavarapu-Charyulu, "Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model, " International Journal of Cancer, vol. 131, no. 2, pp. 377-386, 2012.
45. Information notices on occupational diseases: A guide to diagnosis (2009). Luxembourg: office for official publications of the European communities, " March 2017, https://osha.europa.eu/fi/legislation/guidelines/informationnotices-on-occupational-diseases-A-guide-To-diagnosis.